Sernova Provides Positive Clinical and Platform Portfolio Update
(via TheNewswire)
Type 1 diabetes (T1D) Cohort 2 patient data demonstrates favorable islet engraftment and long-term survival of human donor islets in the Cell Pouch
First treated Cohort 1 patient in the T1D clinical trial to celebrate four years of insulin independence and normalized HbA1c
With recent positive findings in post-surgical hypothyroidism large animal study, Sernova anticipates filing an Investigational New Drug (IND) application in 2024
Additional chronic disease indications identified for further pipeline expansion with a focus on endocrine disorders
LONDON, Ontario; BOSTON, Massachusetts – TheNewswuire – April 2, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenera...